Article
Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Annals of hematology - 1 Oct 2011
Vangsted Annette J, Klausen Tobias W, Abildgaard Niels, Andersen Niels F, Gimsing Peter, Gregersen Henrik, Nexø Bjørn A, Vogel Ulla
Abstract excerpt
Little is known on the impact of polymorphisms in the IL1B gene on outcome in multiple myeloma. In a population-based study of 348 Danish myeloma patients treated with high-dose treatment (HDT), 146 patients treated with INF-α maintenance treatment, and in 243 patients with relapse, we analysed the impact on outcome of HDT, INF-α maintenance treatment, and treatment with thalidomide and bortezomib at relapse, in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.